^
Association details:
Biomarker:ALK F856S
Cancer:Leukemia
Drug:TAE-684 (ALK inhibitor, LRRK2 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

Therapeutically targetable ALK mutations in leukemia

Excerpt:
NVP-TAE684 inhibited the cell survival and proliferation of Ba/F3 ALK A348D and ALK F856S cells with IC50s of 2.5 nM and ~0.5 nM respectively.
DOI:
https://dx.doi.org/10.1158%2F0008-5472.CAN-14-1576